Overview
Neurópixel Therapeutics develops minimally invasive, light-based neuromodulation implants that use optogenetic stimulation to treat refractory epilepsy and chronic pain.
More in Neuromodulation
Latest industry news
Merge Labs Gets Competition as New Rival Neurotech Startup Enters the Consumer BCI Arena
2026-10-31 · Industry
Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone
2026-10-30 · Product
Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One
2026-10-29 · Research
NeuroXess Raises 700 Million Yuan in Series B to Push 'Three-Comprehensive' BCI Into Clinical Trials
2026-10-28 · Funding
Company details
Category
⚡ Neuromodulation
Location
San Diego, CA
Funding
Series A — $22M
Website
neurópixeltherapeutics.comListed
2026-09-21
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →